Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats

Pharmacological Research

Volumn 62, Issue 5, 2010, Pages 450-456

  Camarasa, Jorge ^a   Rodrigo, Teresa ^a   Pubill, David ^a   Escubedo, Elena ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Learning; Memantine; Memory; Methamphetamine; Morris water maze; Object recognition

Indexed keywords

AMPHETAMINE DERIVATIVE; BUNGAROTOXIN RECEPTOR; MEMANTINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; LEARNING; LEARNING DISORDER; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; TASK PERFORMANCE;

ANIMALS; BODY TEMPERATURE; DOPAMINE UPTAKE INHIBITORS; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMANTINE; MEMORY; MEMORY DISORDERS; METHAMPHETAMINE; NICOTINIC ANTAGONISTS; RATS; RATS, LONG-EVANS; RECEPTORS, NICOTINIC;

EID: 77956894853     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.05.004     Document Type: Article

References (43)

1. Cretzmeyer M., Sarrazin M.V., Huber D.L., Block R.I., Hall J.A. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat 2003, 24:267-277.
2. Salo R., Ursu S., Buonocore M.H., Leamon M.H., Carter C. Impaired prefrontal cortical function and disrupted adaptive control in methamphetamine abusers: a functional magnetic resonance imaging study. Biol Psychiatr 2009, 65:706-709.
3. Simon S.L., Dacey J., Glynn S., Rawson R., Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat 2004, 27:59-66.
4. Kalechstein A.D., Newton T.F., Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatr Clin Neurosci 2003, 15:215-220.
5. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatr Clin Neurosci 2003, 15:317-325.
6. Kogan F.J., Nichols W.K., Gibb J.W. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol 1976, 36:363-371.
7. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 1982, 235:93-103.
8. Ellison G., Eison M.S., Huberman H.S., Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science 1978, 201:276-278.
9. Escubedo E., Guitart L., Sureda F.X., Jimenez A., Pubill D., Pallas M., et al. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res 1998, 814:120-126.
10. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994, 270:741-751.
11. Pubill D., Canudas A.M., Pallas M., Camins A., Camarasa J., Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedeberg's Arch Pharmacol 2003, 367:490-499.
12. Nagai T., Takuma K., Dohniwa M., Ibi D., Mizoguchi H., Kamei H., et al. Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol. Psychopharmacology (Berlin) 2007, 194:21-32.
13. Schroder N., O'Dell S.J., Marshall J.F. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse 2003, 49:89-96.
14. He J., Yang Y., Yu Y., Li X., Li X.M. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav Brain Res 2006, 172:39-45.
15. Arai S., Takuma K., Mizoguchi H., Ibi D., Nagai T., Kamei H., et al. GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice. Eur J Pharmacol 2009, 602:101-104.
16. Aracava Y., Pereira E.F., Maelicke A., Albuquerque E.X. Memantine blocks alpha7 nicotinic acetylcholine receptors more potently than n-methyl-d-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 2005, 313:928-929.
17. Escubedo E., Chipana C., Perez-Sanchez M., Camarasa J., Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J Pharmacol Exp Ther 2005, 315:658-667.
18. Chipana C., Torres I., Camarasa J., Pubill D., Escubedo E. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 2008, 54:1254-1263.
19. Camarasa J., Marimón J.M., Rodrigo T., Escubedo E., Pubill D. Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats. Eur J Pharmacol 2008, 589:132-139.
20. Aggleton J.P. One-trial object-recognition by rats. Q J Exp Psychol 1985, 37:279-294.
21. Ennanceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1. Behavioural data. Behav Brain Res 1988, 31:47-59.
22. Rodrigo T., Chamizo V.D., McLaren I.P.L., Mackintosh N.J. Blocking in the spatial domain. J Exp Psychol 1997, 23:110-118.
23. Prados J., Trobalon J.B. Locating an invisible goal in a water maze requires at least two landmarks. Psychobiology 1998, 26:42-48.
24. Pubill D.A., Pallàs M., Camarasa J., Escubedo E. Carnosine prevents methamphetamine-induced gliosis but not dopamine-terminal loss in rats. Eur J Pharmacol 2002, 448:165-168.
25. Mordenti J., Chappell W. The use of interspecies scaling in toxicokinetics. Toxicokinetics in new drug development 1989, 42-96. Pergamon Press, New York. A. Yacobi, J. Kelly, V. Batra (Eds.).
26. Brennan K., Johnstone A., Fitzmaurice P., Lea R., Schenk S. Chronic benzylpiperazine exposure produces behavioral sensitization and cross-sensitization to methamphetamine. Drug Alcohol Depend 2007, 88:204-213.
27. Herbert C.E., Hughes R.N. A comparison of 1-benzylpiperazine and methamphetamine in their acute effects on anxiety-related behavior of hooded rats. Pharmacol Biochem Behav 2009, 92:243-250.
28. Misztal M., Danysz W. Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance. Behav Pharmacol 1995, 6:550-561.
29. Zajaczkowski W., Quack G., Danysz W. Infusion of (±)-MK-801 and memantine: contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996, 296:239-246.
30. Barber T.A., Meyers R.A., McGettigan B.F. Memantine improves memory for taste-avoidance learning in day-old chicks exposed to isolation stress. Pharmacol Biochem Behav 2010, 95:203-208.
31. Barber T.A., Haggarty M.K. Memantine ameliorates scopolamine-induced amnesia in chicks trained on taste-avoidance learning. Neurobiol Learn Mem 2010, 93:540-545.
32. Bisagno V., Ferguson D., Luine V.N. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res 2002, 940:95-101.
33. Belcher A.M., O'Dell S.J., Marshall J.F. Impaired object recognition memory following methamphetamine, but not pchloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 2005, 30:2026-2034.
34. Winters B.D., Saksida L.M., Bussey T.J. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 2008, 32:1055-1070.
35. Chen H.S., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006, 97:1611-1626.
36. Scarpini E., Scheltens P., Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003, 2:539-547.
37. Chipana C., Camarasa J., Pubill D., Escubedo E. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 2008, 29:179-183.
38. Barnes C.A., Danysz W., Parsons C.G. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996, 8:565-571.
39. French E.D., Ferkany J., Abreu M., Levenson S. Effects of competitive N-methyl-d-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacology 1991, 30:1039-1046.
40. Hargreaves E.L., Cain D.P. MK801-induced hyperactivity: duration of effects in rats. Pharmacol Biochem Behav 1995, 51:13-19.
41. Cain D.P., Saucier D., Hall J., Hargreaves E.L., Boon F. Detailed behavioural analysis of water maze acquisition under APV or CNQX: contribution of sensorimotor disturbances to drug-induced acquisition deficits. Behav Neurosci 1996, 110:86-102.
42. Minkeviciene R., Banerjee P., Tanila H. Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology 2008, 54:179-185.
43. Colado M.I., Granados R., O'Shea E., Green A.R. Role of hyperthermia in the protective action of clomethiazole against MDMA (" ecstasy" )-induced neurodegeneration, comparison with the novel NMDA channel blocker ARR15896AR. Br J Pharmacol 1998, 124:479-484.